Concepts (130)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 8 | 2020 | 256 | 3.210 |
Why?
|
| Blood Platelets | 8 | 2020 | 206 | 3.120 |
Why?
|
| Ischemic Attack, Transient | 4 | 2020 | 26 | 2.020 |
Why?
|
| Cognition Disorders | 4 | 2019 | 186 | 1.320 |
Why?
|
| Carotid Stenosis | 3 | 2014 | 27 | 1.300 |
Why?
|
| Cognitive Dysfunction | 5 | 2024 | 265 | 1.040 |
Why?
|
| Veterans | 2 | 2019 | 69 | 0.970 |
Why?
|
| Cognition | 3 | 2025 | 327 | 0.700 |
Why?
|
| Aged | 15 | 2025 | 5525 | 0.650 |
Why?
|
| Stroke, Lacunar | 1 | 2020 | 3 | 0.640 |
Why?
|
| Platelet Activation | 1 | 2019 | 54 | 0.610 |
Why?
|
| Dementia, Vascular | 1 | 2019 | 51 | 0.580 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2019 | 76 | 0.570 |
Why?
|
| Brain Ischemia | 1 | 2019 | 87 | 0.570 |
Why?
|
| Blood Coagulation | 1 | 2019 | 120 | 0.560 |
Why?
|
| Middle Aged | 14 | 2025 | 7310 | 0.550 |
Why?
|
| Risk Factors | 7 | 2020 | 2111 | 0.500 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 461 | 0.470 |
Why?
|
| Male | 15 | 2025 | 13772 | 0.460 |
Why?
|
| Humans | 22 | 2025 | 28585 | 0.440 |
Why?
|
| Carotid Artery, Internal | 1 | 2014 | 19 | 0.440 |
Why?
|
| Asymptomatic Diseases | 1 | 2014 | 17 | 0.440 |
Why?
|
| Indians, North American | 1 | 2019 | 534 | 0.430 |
Why?
|
| Antihypertensive Agents | 1 | 2014 | 56 | 0.430 |
Why?
|
| Carotid Artery Diseases | 1 | 2014 | 37 | 0.430 |
Why?
|
| Medication Adherence | 1 | 2014 | 48 | 0.420 |
Why?
|
| Smoking Cessation | 1 | 2019 | 412 | 0.420 |
Why?
|
| Hypoglycemic Agents | 1 | 2014 | 109 | 0.410 |
Why?
|
| Female | 13 | 2025 | 15472 | 0.410 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2014 | 191 | 0.390 |
Why?
|
| Aged, 80 and over | 5 | 2025 | 2045 | 0.370 |
Why?
|
| Hypertension | 3 | 2023 | 309 | 0.310 |
Why?
|
| Time Factors | 4 | 2019 | 1600 | 0.310 |
Why?
|
| Cerebral Hemorrhage | 3 | 2023 | 93 | 0.310 |
Why?
|
| Mental Status and Dementia Tests | 2 | 2019 | 14 | 0.300 |
Why?
|
| Catheterization, Central Venous | 1 | 2007 | 38 | 0.270 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 480 | 0.260 |
Why?
|
| Platelet Count | 2 | 2019 | 111 | 0.240 |
Why?
|
| Risk Assessment | 2 | 2019 | 622 | 0.240 |
Why?
|
| Thrombosis | 1 | 2007 | 150 | 0.240 |
Why?
|
| Recurrence | 2 | 2020 | 325 | 0.240 |
Why?
|
| Anticoagulants | 1 | 2007 | 295 | 0.230 |
Why?
|
| Niacinamide | 1 | 2025 | 32 | 0.230 |
Why?
|
| Smoking | 2 | 2019 | 476 | 0.230 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 524 | 0.220 |
Why?
|
| NAD | 1 | 2025 | 104 | 0.220 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2023 | 14 | 0.200 |
Why?
|
| Peripheral Arterial Disease | 1 | 2025 | 144 | 0.190 |
Why?
|
| Dietary Supplements | 1 | 2025 | 265 | 0.190 |
Why?
|
| Neurovascular Coupling | 1 | 2024 | 154 | 0.190 |
Why?
|
| White Matter | 1 | 2023 | 90 | 0.190 |
Why?
|
| Pilot Projects | 2 | 2025 | 458 | 0.190 |
Why?
|
| Venous Insufficiency | 1 | 2021 | 2 | 0.180 |
Why?
|
| Varicose Veins | 1 | 2021 | 3 | 0.180 |
Why?
|
| Dementia | 1 | 2023 | 95 | 0.180 |
Why?
|
| Cardiovascular System | 1 | 2021 | 40 | 0.180 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 988 | 0.160 |
Why?
|
| Sporotrichosis | 1 | 2019 | 4 | 0.150 |
Why?
|
| Arthritis, Infectious | 1 | 2019 | 11 | 0.150 |
Why?
|
| Serotonin Uptake Inhibitors | 1 | 2019 | 26 | 0.150 |
Why?
|
| Hyperlipidemias | 1 | 2019 | 37 | 0.150 |
Why?
|
| Valsalva Maneuver | 1 | 2018 | 8 | 0.150 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 208 | 0.140 |
Why?
|
| Diabetes Complications | 1 | 2019 | 66 | 0.140 |
Why?
|
| Aspirin | 1 | 2019 | 125 | 0.140 |
Why?
|
| Prognosis | 2 | 2017 | 807 | 0.140 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2019 | 134 | 0.140 |
Why?
|
| Prevalence | 1 | 2019 | 510 | 0.130 |
Why?
|
| Thrombin | 1 | 2017 | 69 | 0.130 |
Why?
|
| Adult | 2 | 2019 | 7922 | 0.130 |
Why?
|
| Microcirculation | 1 | 2017 | 113 | 0.130 |
Why?
|
| Microvessels | 1 | 2017 | 86 | 0.120 |
Why?
|
| Collagen | 1 | 2017 | 156 | 0.120 |
Why?
|
| Cerebrovascular Circulation | 1 | 2017 | 224 | 0.110 |
Why?
|
| Hematologic Tests | 1 | 2014 | 7 | 0.110 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 1026 | 0.110 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2014 | 26 | 0.110 |
Why?
|
| Cohort Studies | 2 | 2014 | 893 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 194 | 0.110 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 226 | 0.110 |
Why?
|
| Flow Cytometry | 1 | 2014 | 291 | 0.100 |
Why?
|
| Constriction, Pathologic | 1 | 2013 | 36 | 0.100 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2013 | 59 | 0.100 |
Why?
|
| Endothelium, Vascular | 2 | 2025 | 328 | 0.090 |
Why?
|
| Longitudinal Studies | 2 | 2023 | 426 | 0.080 |
Why?
|
| Reminder Systems | 1 | 2009 | 11 | 0.080 |
Why?
|
| Internal Medicine | 1 | 2009 | 28 | 0.070 |
Why?
|
| United States | 1 | 2014 | 2201 | 0.070 |
Why?
|
| Mass Screening | 1 | 2009 | 156 | 0.070 |
Why?
|
| Risk | 1 | 2007 | 137 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2009 | 141 | 0.070 |
Why?
|
| Curriculum | 1 | 2009 | 296 | 0.060 |
Why?
|
| Venous Thrombosis | 1 | 2007 | 98 | 0.060 |
Why?
|
| Pulmonary Embolism | 1 | 2007 | 126 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2023 | 834 | 0.060 |
Why?
|
| Hemorrhage | 1 | 2007 | 265 | 0.060 |
Why?
|
| Internship and Residency | 1 | 2009 | 250 | 0.060 |
Why?
|
| Pyridinium Compounds | 1 | 2025 | 27 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2025 | 190 | 0.060 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2024 | 74 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2023 | 54 | 0.050 |
Why?
|
| Neuropsychological Tests | 1 | 2023 | 247 | 0.050 |
Why?
|
| Pandemics | 1 | 2023 | 196 | 0.050 |
Why?
|
| Mitochondria | 1 | 2025 | 396 | 0.040 |
Why?
|
| Disease Progression | 1 | 2023 | 475 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2007 | 2402 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2025 | 671 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2023 | 1272 | 0.040 |
Why?
|
| Itraconazole | 1 | 2019 | 9 | 0.040 |
Why?
|
| Metacarpophalangeal Joint | 1 | 2019 | 5 | 0.040 |
Why?
|
| Swimming | 1 | 2018 | 32 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2019 | 67 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2019 | 149 | 0.030 |
Why?
|
| Brain | 1 | 2023 | 753 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 378 | 0.030 |
Why?
|
| Vascular Remodeling | 1 | 2017 | 14 | 0.030 |
Why?
|
| Matrix Metalloproteinases | 1 | 2017 | 31 | 0.030 |
Why?
|
| Memory | 1 | 2017 | 76 | 0.030 |
Why?
|
| Memory Disorders | 1 | 2017 | 50 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2017 | 221 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2017 | 117 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2017 | 292 | 0.030 |
Why?
|
| Age Factors | 1 | 2017 | 734 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2013 | 732 | 0.020 |
Why?
|
| Aging | 1 | 2017 | 979 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 2009 | 60 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2009 | 95 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2009 | 172 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2009 | 164 | 0.020 |
Why?
|
| Animals | 1 | 2017 | 10583 | 0.010 |
Why?
|